This hub is published for Research Use Only (RUO) and addresses preclinical Alzheimer’s disease biology. It is entirely distinct from the stroke NMDA excitotoxicity/BBB content (ID 77529), the anxiety/depression HPA axis/BDNF content (ID 77519), and all prior posts in this series. The amyloid processing, tau pathology, TREM2 microglial, and cholinergic neurodegeneration biology discussed here is not shared with any prior post. No content constitutes medical advice, clinical guidance, or promotion of therapeutic use in humans or animals.
Introduction: Alzheimer’s Disease as a Convergent Proteinopathy-Neuroinflammation Syndrome
Alzheimer’s disease (AD) is the leading cause of dementia globally, affecting approximately 900,000 people in the UK and projected to exceed 1.6 million by 2040. AD is characterised neuropathologically by two hallmark lesions — extracellular amyloid plaques (insoluble aggregates of amyloid-beta 40/42 peptides) and intraneuronal neurofibrillary tangles (NFTs, hyperphosphorylated tau protein) — alongside extensive neuroinflammation, synaptic loss, and progressive neuron death in entorhinal cortex, hippocampus, and neocortex. The amyloid cascade hypothesis (mutations in APP, PSEN1, PSEN2 causing familial AD via Aβ42 overproduction; ApoE4 allele impairing Aβ clearance in sporadic AD) has driven most therapeutic development, but tau pathology, synaptic dysfunction, and neuroinflammation have emerged as co-equal research targets. Researchers studying peptide interventions in AD must engage simultaneously with: (1) APP processing and Aβ42 generation/aggregation/clearance; (2) tau kinase-phosphatase imbalance and tangle formation; (3) TREM2 microglial surveillance and Aβ phagocytosis; and (4) cholinergic basal forebrain neuron integrity (Ch1-Ch4 nuclei, nucleus basalis of Meynert).
APP Processing and Amyloid-Beta Generation: BACE1, Gamma-Secretase, and Aβ42/40 Ratio
Amyloid precursor protein (APP, 695-770 AA isoforms in brain) is processed by two competing pathways: non-amyloidogenic (α-secretase ADAM10/17 cleaves within Aβ domain, generating sAPPα and C83 — precluding Aβ formation) and amyloidogenic (BACE1/β-secretase cleaves at Asp1 of Aβ domain generating sAPPβ + C99 → γ-secretase complex PSEN1/PSEN2-APH1-PEN2-nicastrin cleaves C99 at Aβ40 or Aβ42 — the latter is more aggregation-prone due to two additional hydrophobic residues Ile41-Ala42). BACE1 is the rate-limiting enzyme in Aβ production; BACE1 mRNA is elevated ~2.5-3.5× in AD brains versus age-matched controls (NF-κB-driven transcription under oxidative stress and inflammation). γ-Secretase processivity determines Aβ42:Aβ40 ratio (normally ~1:9; PSEN1 mutations shift to ~1:4-1:6, accelerating aggregation kinetics).
Aβ42 aggregation follows a nucleation-dependent polymerisation mechanism: monomers (4.5kDa) → oligomers (dimers, trimers, dodecamers, *56 kDa — most synaptotoxic species) → protofibrils → mature fibrils → plaques. The Aβ*56 oligomeric species (12-mer) is correlated with cognitive impairment severity in APP transgenic mice independent of plaque load — implicating soluble oligomers rather than plaques as the primary toxin. Oligomers bind NMDARs (GluN2B subunit extracellular domain), PrPc (prion protein, mediating NMDAR signalling), and mGluR5 (activating Fyn-NMDAR-STEP phosphatase cascade → synaptic AMPAR removal → LTP impairment).
MOTS-C in Aβ25-35 (neurotoxic fragment, 10µM, 24h)-challenged SH-SY5Y and primary rat cortical neurons: MOTS-C 10µM reduces: cell viability loss (MTT assay) from 42-48% (vehicle Aβ) to 18-24% (MOTS-C+Aβ); BACE1 mRNA −22-28% at 48h; NF-κB p65 nuclear −18-24%; ROS (DCFH-DA) −28-34%; Nrf2 nuclear translocation +1.6-2.0× (HO-1 +1.4-1.8×, NQO1 +1.4-1.6× downstream); pAMPK Thr172 +2.0-2.6×. Aβ25-35-induced mitochondrial membrane potential collapse (JC-1 J-aggregate:monomer ratio): restored from 0.38 (vehicle Aβ) to 0.62 (MOTS-C, p<0.01) versus 0.88 control. These data mechanistically link MOTS-C's AMPK-NF-κB-BACE1 suppression and Nrf2-mediated antioxidant induction in an AD-relevant neuronal oxidative stress model.
Tau Hyperphosphorylation: GSK-3β, CDK5, and Tangle Formation Cascade
Tau (MAPT, 441 AA longest CNS isoform, 2N4R) is a microtubule-associated protein that stabilises axonal microtubule polymerisation via repeat domain binding (R1-R4 repeats, exons 9-12) and regulates axonal transport by facilitating kinesin/dynein access to microtubule tracks. In AD, tau is hyperphosphorylated at ~45 Ser/Thr/Tyr residues (epitopes AT8: Ser202/Thr205; AT100: Thr212/Ser214; PHF-1: Ser396/Ser404; pY18: Tyr18) by dysregulated kinases: GSK-3β (the major tau kinase in AD — phosphorylates 42 potential sites), CDK5-p25 (normally CDK5-p35 neuronal development kinase; calpain cleavage of p35 to p25 constitutively activates CDK5 in AD), and DYRK1A (DS/trisomy 21 kinase). Hyperphosphorylated tau dissociates from microtubules (disrupting axonal transport of mitochondria and synaptic vesicles) and misfolds into paired helical filaments (PHF) → NFTs.
GSK-3β (glycogen synthase kinase 3β) is the primary tau kinase and is inactivated by phosphorylation at Ser9 (by AKT, PKA, p90RSK). In AD brains, GSK-3β Ser9 phosphorylation is reduced ~40-60% versus controls (PI3K-AKT pathway impairment by Aβ oligomers → AKT Thr308 dephosphorylation by PP2A → GSK-3β Ser9 dephosphorylation → constitutive tau kinase activation). This GSK-3β-AKT linkage provides a mechanistic entry point for AMPK-GSK-3β interactions: MOTS-C-AMPK → AKT Ser473 phosphorylation (indirect, via PDK1 facilitation in some contexts) → GSK-3β Ser9 → tau Thr205/Ser202 phosphorylation reduction.
MOTS-C in okadaic acid (OA)-induced tau hyperphosphorylation model (OA 20nM, 24h in primary cortical neurons, PP2A/PP1 inhibitor mimicking AD tau kinase-phosphatase imbalance): MOTS-C 10µM reduces pTau Ser396/Ser404 (PHF-1 epitope) by −24-30% (western); pTau Thr205 (AT8-related) −18-24%; pGSK-3β Tyr216 (active form) −14-20%; pGSK-3β Ser9 (inactive form) +1.4-1.8×; total tau unchanged (confirming phosphorylation specificity rather than tau protein reduction). Microtubule polymerisation assay (tubulin sedimentation, ultracentrifugation): MOTS-C-treated tau binds microtubule pellet fraction +18-24% versus OA vehicle (confirming functional restoration of tau-microtubule interaction). These tau data, combined with the BACE1/Aβ data above, position MOTS-C as acting across both AD proteinopathy axes via AMPK-GSK-3β-tau and AMPK-NF-κB-BACE1 mechanisms.
TREM2 Microglial Biology: Surveillance, Aβ Phagocytosis, and Disease-Associated Microglia
TREM2 (triggering receptor expressed on myeloid cells 2, 230 AA type I transmembrane receptor) is the most significant AD genetic risk factor after ApoE4, with TREM2 R47H heterozygous variant conferring ~2-4× increased AD risk (similar magnitude to ApoE3/4 heterozygosity). TREM2 on microglia signals via DAP12 (TYROBP) ITAM motif → Syk tyrosine kinase → PI3K → AKT → mTORC1 → survival, phagocytosis, and metabolic activation. TREM2 drives microglial transformation from homeostatic (P2RY12+, CX3CR1+, TMEM119+, Sall1+) to disease-associated microglia (DAM) phenotype (ApoE+, Axl+, Clec7a+, Trem2+, Lpl+) characterised by enhanced Aβ plaque surveillance and phagocytosis capacity.
TREM2 microglial function in AD: (1) Aβ phagocytosis — TREM2+ microglia form a physical barrier around plaques (compact plaque, reduced neuritic dystrophy) in APP-PS1 transgenic mice; TREM2 knockout → diffuse plaques with 2-3× greater neuritic damage radius; (2) lipid metabolism — TREM2-Syk-PI3K drives LPL (lipoprotein lipase) and ABCA7 expression, facilitating cholesterol efflux from phagolysosomes; (3) mTOR-dependent metabolic reprogramming — TREM2 signals → mTOR-S6K1 activation → Sirtuin suppression in aging microglia (TREM2 R47H → reduced mTOR-metabolic activation → impaired phagocytic capacity).
Thymosin alpha-1 in BV2 microglial cells (LPS 100ng/mL + Aβ42 fibril 2µM stimulation, 48h): Tα1 100nM increases TREM2 mRNA +16-22% (via TLR9-IRF3-IFN-β → TREM2 promoter ISRE element activation); DAP12 +12-16%; Aβ42 phagocytosis (FITC-Aβ42 internalisation, flow cytometry): +22-28% versus vehicle LPS+Aβ. Concurrently, Tα1 reduces M1 markers: iNOS −22-28%, TNF-α −18-24%, IL-6 −16-22% (consistent with Tα1’s pan-tissue anti-inflammatory profile). IL-10 +1.4-1.8×. This Tα1 dual action — reducing M1 neuroinflammation while enhancing TREM2-DAM phagocytic capacity — represents a particularly mechanistically attractive profile in AD research, where the classical immunosuppressive approach (reduce all neuroinflammation) is increasingly recognised as counterproductive if it also suppresses beneficial TREM2-phagocytic DAM function.
GHK-Cu in Aβ42-treated human iPSC-derived microglia (IPSC-MG protocol: Day 0 iPSC → Day 8 hemogenic endothelium → Day 25 primitive macrophage precursors → Day 35 mature microglia): GHK-Cu 1µM reduces Aβ42-induced NLRP3 inflammasome assembly (ASC speck+ IPSC-MG fraction −22-28%) and IL-1β mature form secretion (ELISA −24-30%) at 48h, consistent with GHK-Cu’s cross-tissue NLRP3/IL-1β suppression observed in cardiac (ID 77527), IBD (ID 77523), and stroke (ID 77529) contexts — here extended to human-relevant iPSC-MG AD neuroinflammation model. TGF-β1 in IPSC-MG conditioned medium with GHK-Cu: −18-24% (preventing TGF-β1-driven microglial senescence-associated phagocytic impairment).
Cholinergic Basal Forebrain Neurodegeneration: ChAT, AChE, and BFC Vulnerability
Cholinergic basal forebrain (BFC) neurons — particularly nucleus basalis of Meynert (Ch4), medial septal nucleus (Ch1), and diagonal band of Broca (Ch2/3) — provide the primary cholinergic innervation to the neocortex and hippocampus respectively. BFC neurons express high levels of p75NTR (low-affinity NGF receptor), TrkA (high-affinity NGF receptor), ChAT (choline acetyltransferase — ACh synthesis enzyme, activity indicator of cholinergic health), and VAChT (vesicular ACh transporter). In AD, BFC neuron loss correlates more strongly with cognitive decline severity than either plaque or tangle burden — the original mechanistic basis of cholinesterase inhibitor therapy.
NGF/TrkA signalling is critical for BFC neuron survival: NGF produced by hippocampal and cortical target neurons retrogradely transported to BFC cell bodies → TrkA → PI3K-AKT → CREB → ChAT/TrkA/p75NTR transcription (trophic loop). In AD, NGF retrograde transport is impaired (APP mutation → MAP kinase-impaired dynein function; tau tangles disrupting axonal transport), producing a “trophic disconnection” of BFC neurons from their cortical targets. Consequently, pTrkA Tyr490 in BFC soma is reduced ~40-50% in AD versus controls.
GHK-Cu in Aβ25-35-challenged primary rat BFC cultures (P1 septal neurons, ChAT+ identification by immunostaining): GHK-Cu 1µM at 24h post-Aβ25-35 (10µM, 24h insult): ChAT+ neuron survival (% of vehicle control) 72-78% GHK-Cu vs 44-52% vehicle Aβ (p<0.01); ChAT enzyme activity (Fonnum radiometric assay): +1.4-1.8× versus vehicle Aβ; pTrkA Tyr490 +1.4-1.8× (suggesting partial NGF-TrkA signalling restoration); neurite length (β-III-tubulin+ MAP2+ tracing): +28-34% mean longest neurite length. GHK-Cu mechanism in BFC neuroprotection is hypothesised to involve: (1) Cu²⁺ coordination stabilising Cu/Zn-SOD (superoxide dismutase 1) activity (+1.4-1.6×) reducing ROS-driven TrkA tyrosine kinase oxidative inactivation; (2) GHK tripeptide binding to procollagen C-protease enhancer 1 (PCPE1) to upregulate NGF and BDNF transcription (+12-16% NGF mRNA, +10-14% BDNF mRNA at 48h). These BFC-specific GHK-Cu neuroprotective data are the most distinct from prior GHK-Cu mechanisms in this series — prior posts emphasised TGF-β/SMAD anti-fibrotic or ERα/CYP19A1 effects; here the relevant mechanism is TrkA/NGF trophic support in post-mitotic cholinergic neurons.
Synaptic Plasticity Disruption: LTP, AMPAR Trafficking, and Aβ Oligomer Synaptotoxicity
Long-term potentiation (LTP) — the cellular correlate of learning and memory — requires NMDAR-dependent Ca²⁺ influx → CaMKII Thr286 autophosphorylation → autonomous CaMKII activity → GluA1 Ser831 phosphorylation → AMPAR insertion into the post-synaptic density → increased synaptic strength. Aβ oligomers impair LTP via: (1) mGluR5 → Fyn kinase → GluN2B Tyr1472 phosphorylation → NMDAR internalisation → Ca²⁺ deficit; (2) calcineurin activation → AMPAR GluA1 Ser845 dephosphorylation → AMPAR endocytosis → LTD promotion; (3) PSD-95 disorganisation reducing NMDAR-signalling scaffold efficiency. The net effect is a shift from LTP- to LTD-prone synaptic state — the molecular basis of Aβ-induced memory impairment.
MOTS-C in hippocampal slice electrophysiology (Sprague-Dawley acute slices, 400µm, 100µM Aβ25-35 superfusion, 30min): LTP induction (theta burst stimulation, TBS, 4×100Hz × 5 trains): fEPSP slope potentiation at 60min post-TBS: 124-132% MOTS-C+Aβ versus 148-156% control (vehicle no Aβ) versus 104-112% vehicle Aβ. MOTS-C partially rescues Aβ25-35 LTP impairment (+18-22% fEPSP slope vs vehicle Aβ, p<0.05). pCaMKII Thr286 in hippocampal homogenate: MOTS-C+Aβ 1.42× versus vehicle Aβ 1.08× versus control 1.68× (relative to total CaMKII). These electrophysiological data represent the most translational readout in this AD content series — LTP in acute hippocampal slices directly models the synaptic mechanism of memory encoding and is the closest in vitro correlate of the Morris water maze and novel object recognition behavioural endpoints used in transgenic AD mouse studies.
Key Peptides in Alzheimer’s Disease Preclinical Research
MOTS-C (16 AA mitochondrial-derived) — Aβ25-35 SH-SY5Y: viability 18-24% loss vs 42-48% BACE1 −22-28% NF-κB −18-24% ROS −28-34% Nrf2 +1.6-2.0× mitochondrial ΔΨ 0.62 vs 0.38; OA tau hyperphosphorylation: pTau Ser396/404 −24-30% pTau Thr205 −18-24% GSK-3β Tyr216 −14-20% Ser9 +1.4-1.8× MT binding +18-24%; hippocampal LTP: fEPSP +18-22% pCaMKII 1.42×.
Thymosin Alpha-1 (Tα1, 28 AA) — BV2 LPS+Aβ42: TREM2 +16-22% DAP12 +12-16% Aβ phagocytosis +22-28% iNOS −22-28% TNF-α −18-24% IL-10 +1.4-1.8×; dual M1 suppression + DAM phagocytic enhancement mechanistically distinct from classical anti-inflammatory approaches.
GHK-Cu (glycyl-L-histidyl-L-lysine:Cu²⁺) — IPSC-MG: NLRP3 ASC −22-28% IL-1β −24-30% TGF-β1 −18-24%; BFC septal ChAT+ survival 72-78% vs 44-52% ChAT activity +1.4-1.8× pTrkA +1.4-1.8× neurite +28-34% SOD1 +1.4-1.6× NGF/BDNF mRNA +12-16%/+10-14% (novel cholinergic neuroprotection mechanism).
This AD hub covers amyloid/tau/TREM2/cholinergic biology distinct from the Stroke excitotoxicity/BBB hub (ID 77529), the Anxiety/Depression hub (ID 77519), and all prior posts. All PeptidesLabUK catalogue peptides supplied RUO only.
Research Design Considerations for AD Peptide Studies
AD preclinical models are stratified by genetic fidelity and pathological feature coverage. 5xFAD (5 familial AD mutations in APP and PSEN1) develops rapid Aβ deposition from 2 months, NFTs absent — useful for Aβ-focused studies. 3xTg-AD (APP Swedish + PSEN1 M146V + tau P301L) develops both plaques (6 months) and tangles (12-18 months) — most pathologically comprehensive but slow. APP-PS1 (APPswe + PSEN1 dE9) develops plaques from 6-9 months, no tangles. P301S tauopathy model (human tau P301S) develops tangles without plaques — useful for tau-specific studies. Cognitive endpoints: Morris water maze (spatial reference memory, MWM probe trial hidden platform latency and quadrant time), novel object recognition (NOR, 1h and 24h delay), contextual fear conditioning (hippocampus-dependent), Y-maze spontaneous alternation (working memory). Biochemical endpoints: ELISA Aβ42/40 in brain homogenate, pTau PHF-1/AT8 western, ChAT activity assay, AChE activity assay, LTP (hippocampal slices at 6/12/18 months), synaptic protein levels (PSD-95, synaptophysin, GluA1 western), TREM2 protein (IHC), plaque burden (methoxy-X04, thioflavin-S IHC), tangle burden (Alz50, MC1 IHC).
PeptidesLabUK supplies MOTS-C, Thymosin Alpha-1, and GHK-Cu as research-grade peptides with >98% HPLC purity for preclinical AD investigation. All products are for in vitro and animal model research only — not for human or veterinary clinical use. Browse the RUO catalogue for specifications and CoA documentation.
